share_log

GlaxoSmithKline | 6-K: Gsk Announces Positive Results from Dreamm-8 Phase Iii Trial for Blenrep Versus Standard of Care Combination in Relapsed/Refractory Multiple Myeloma

SEC announcement ·  Mar 7 06:14
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more